KPV vs LL-37
Both are natural human immune peptides with no controlled human trials, but they push in opposite directions: KPV dampens inflammatory signaling, LL-37 can drive it.
Short answer
Neither KPV nor LL-37 has much human evidence; both are graded preclinical / minimal, so trials cannot say which works better. KPV is the one sold for inflammation, gut and wound healing, while LL-37 targets infection, immunity and healing. Both are sold gray-market as research chemicals.
KPV
The anti-inflammatory tail of α-MSH, with real mechanism and real mouse data — but essentially no human trials.
Full KPV evidence reviewLL-37
Cathelicidin
Genuine innate-immunity biology, but its therapeutic use is preclinical — and the same peptide is implicated in driving inflammatory disease.
Full LL-37 evidence reviewKPV vs LL-37: head to head
- FDA status / approved use
KPV
Unapproved; sold gray-market as a research peptide of unverified contentLL-37
Unapproved research chemical; not an approved drug for any indication- Marketed for
KPV
Inflammation, gut, wound healingLL-37
Infection, immunity, healing- Outcome areas
KPV
Immune function / inflammation; Gut health; Injury recovery / tissue repairLL-37
Immune function / inflammation; Injury recovery / tissue repair- Evidence grade
KPV
Preclinical / minimalLL-37
Preclinical / minimal- How it works
KPV
Enters cells via the PepT1 transporter and dampens inflammatory NF-κB signalingLL-37
Natural human host-defense peptide that disrupts bacterial membranes- Route and dosing
KPV
Oral, topical or injectable products; no established doseLL-37
Injection- Headline human result
KPV
Not establishedLL-37
Not established- Strongest evidence
KPV
Dalmasso, Gastroenterology 2008. Little or no controlled human outcome data for the marketed useKPV evidence reviewPubMed 18061177LL-37
Lande, Nature 2007. Little or no controlled human outcome data for the marketed useLL-37 evidence reviewPubMed 17873860- Key safety signal
KPV
No human safety profile or established dose; products of unverified contentLL-37
Implicated in rosacea, psoriasis and lupus; gray-market vials carry sterility and purity risks- How it is obtained
KPV
Sold gray-market as a research chemical; no approved or legitimately compounded human productLL-37
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| KPV | LL-37 | |
|---|---|---|
| FDA status / approved use | Unapproved; sold gray-market as a research peptide of unverified content | Unapproved research chemical; not an approved drug for any indication |
| Marketed for | Inflammation, gut, wound healing | Infection, immunity, healing |
| Outcome areas | Immune function / inflammation; Gut health; Injury recovery / tissue repair | Immune function / inflammation; Injury recovery / tissue repair |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| How it works | Enters cells via the PepT1 transporter and dampens inflammatory NF-κB signaling | Natural human host-defense peptide that disrupts bacterial membranes |
| Route and dosing | Oral, topical or injectable products; no established dose | Injection |
| Headline human result | Not established | Not established |
| Strongest evidence | Dalmasso, Gastroenterology 2008. Little or no controlled human outcome data for the marketed useKPV evidence reviewPubMed 18061177 | Lande, Nature 2007. Little or no controlled human outcome data for the marketed useLL-37 evidence reviewPubMed 17873860 |
| Key safety signal | No human safety profile or established dose; products of unverified content | Implicated in rosacea, psoriasis and lupus; gray-market vials carry sterility and purity risks |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
Neither has controlled human trials for the uses it is marketed for, and both are unapproved research-only material. KPV is the anti-inflammatory tripeptide tail of alpha-MSH, carried into cells by PepT1 and suppressing NF-kB from the inside, with reproducible mouse colitis data. LL-37 is the single human cathelicidin, with well-documented antimicrobial, immunomodulatory, and wound-healing activity in preclinical work, but it is genuinely double-edged: dysregulated LL-37 is implicated in rosacea, psoriasis, and lupus, so raising it is not obviously beneficial. On safety reasoning alone, LL-37 carries a documented mechanism for harm that KPV does not.
KPV fits if
KPV is the better fit for a reader focused on gut and inflammatory biology who wants the cleaner, one-directional mechanism.
LL-37 fits if
LL-37 is worth reading for the innate-immunity science itself, as long as the two-sided inflammatory risk is read alongside the claimed benefits.
KPV vs LL-37: common questions
- Is either KPV or LL-37 FDA-approved?
- No. KPV is unapproved; sold gray-market as a research peptide of unverified content. LL-37 is an unapproved research chemical; not an approved drug for any indication.
- Which has stronger human evidence, KPV or LL-37?
- Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for KPV is Dalmasso, Gastroenterology 2008; for LL-37, it is Lande, Nature 2007.
- What are the main safety concerns with KPV and LL-37?
- KPV has no human safety profile or established dose; products of unverified content. LL-37 is implicated in rosacea, psoriasis and lupus; gray-market vials carry sterility and purity risks.
Key studies behind each
KPV
- Luger TA, Brzoska T. (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. PubMed 17934097
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PubMed 18061177
- Kelly JM, Moir AJ, Carlson K, et al. (2006). Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides. PubMed 16274845
- Kannengiesser K, Maaser C, Heidemann J, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. PubMed 18092346
LL-37
- Vandamme D, Landuyt B, Luyten W, Schoofs L. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. PubMed 23246832
- Dürr UH, Sudheendra US, Ramamoorthy A. (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. PubMed 16716248
- Gallo RL. (2008). Sounding the alarm: multiple functions of host defense peptides. J Invest Dermatol. PubMed 18071331
- Dzurová L, Holásková E, Pospíšilová H, et al. (2024). Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation. Antibiotics (Basel). PubMed 39858288
The full evidence reviews
- KPV peptide: what the evidence actually shows (benefits, dosage talk, and side effects)
KPV is the anti-inflammatory tripeptide tail of α-MSH, sold for gut, inflammation, wound-healing and skin. The mechanism is real and the mouse data are real — but there are essentially no human trials. A straight read of where the science stands.
Updated August 2026
- LL-37: a real immune peptide, no human proof, and two edges
The human cathelicidin is genuine innate-immunity biology — but its therapeutic use is preclinical, and the same peptide is implicated in inflammatory disease.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm KPV availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: YourHealthRxPeptiYucca HealthRxSpan MDTelos RXDefy Medical